[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights: Esperion Therapeutics (ESPR) President & CEO Sheldon L. Koenig reported the sale of 30,474 common shares on 06/17/2025 at an average price of $1.109 per share, transaction code “S”. Following the disposition, Koenig directly owns 1,541,488 ESPR shares.

The filing notes that the shares were sold solely to cover tax-withholding obligations incurred from the vesting of restricted stock units; the sale was not part of an open-market liquidation for personal gain. No derivative securities were acquired or disposed of, and no Rule 10b5-1 trading plan was indicated.

Because the sale represents roughly 2 % of Koenig’s direct holdings and leaves his ownership position largely intact, the transaction appears routine and is unlikely to materially affect investor perceptions of insider alignment or corporate governance.

Insights

Portfolio Manager

TL;DR: Small, tax-driven sale; insider alignment unchanged.

The CEO’s 30 k-share sale equates to roughly 2 % of his stake and just over $33 k in proceeds. Given the explicit tax-withholding explanation and the remaining 1.54 million-share position, I view the event as non-impactful for valuation or sentiment. No derivatives, no pattern of sequential sales, and no change in senior management status reduce the informational value for trading decisions.

Corporate Governance Expert

TL;DR: Routine Section 16 filing; governance risk minimal.

Form 4 shows compliance with timely reporting and transparent disclosure of the tax-related nature of the sale. The modest size relative to total holdings maintains incentive alignment, and no red flags such as undisclosed 10b5-1 activity or derivative hedging appear. I classify the event as ordinary-course administrative reporting with neutral governance impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Koenig Sheldon L.

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		S		30,474(1)	D	$1.109	1,541,488	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ESPR shares did CEO Sheldon Koenig sell on 06/17/2025?

He sold 30,474 shares of Esperion Therapeutics common stock.

What was the sale price for the ESPR shares disposed by the CEO?

The shares were sold at an average price of $1.109 per share.

Why did Sheldon Koenig sell ESPR shares according to the Form 4?

The filing states the sale was solely to satisfy tax-withholding obligations on vested restricted stock units.

How many ESPR shares does the CEO hold after the reported transaction?

Following the sale, Koenig directly owns 1,541,488 shares of ESPR.

Does the filing mention a Rule 10b5-1 trading plan?

No; the Form 4 does not indicate that the transaction was executed under a Rule 10b5-1 plan.